Our look is new. Our purpose is the same. Learn more about our brand evolution.
[…] difficulty adapting to the physical stresses of an active military life, he was diagnosed with FSHD Type 1. “I never imagined being medically retired from the military due to FSHD […]
[…] talks to see the slides. Click on “video” to watch the recorded talk. Advances in FSHD treatments Getting ready for FSHD clinical trials, Jeff Statland, MD Why we think FSHD […]
[…] leaders to discuss the current state of clinical trial preparedness for facioscapulohumeral muscular dystrophy ( FSHD). The Society is the world’s largest research-focused patient advocacy organization for FSHD, a hereditary […]
[…] expression of the DUX4 gene, considered to be the root cause of muscle damage in FSHD. Michael Dyle Investigating the Molecular Consequences of Reduced NMD in FSHD Skeletal Muscle Myoblasts. […]
[…] trials of drugs intended to increase muscle size, however, drug developers showed little interest in FSHD, even in the decades following the ODA. This changed dramatically with the publication in […]
